18:56 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
21:36 , Aug 23, 2018 |  BC Extra  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
15:14 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Roche scraps taselisib plans based on ASCO data

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said they will not seek approval for taselisib after the Phase III SANDPIPER study to treat metastatic breast cancer showed that the molecule provided limited benefit. However,...
12:28 , Jun 2, 2018 |  BC Extra  |  Clinical News

Roche scraps taselisib plans based on ASCO data

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said they will not seek approval for taselisib after the Phase III SANDPIPER study to treat metastatic breast cancer showed that the molecule provided limited benefit. However,...
07:00 , Aug 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase α (PI3Kα); pyruvate dehydrogenase kinase 1 (PDK1); serum/glucocorticoid regulated kinase 1 (SGK1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting PDK1 or SGK1 could help treat PI3Kα inhibitor-resistant breast cancer. In breast cancer patients, high tumor expression of SGK1 correlated with resistance...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Clinical News

Encorafenib: Interim Phase Ib/II data

Interim data from 102 patients with advanced BRAF mutation-positive mCRC who failed >=1 prior therapy in an open-label, international Phase Ib/II trial showed that once-daily 200 mg oral encorafenib plus Erbitux cetuximab and alpelisib led...
07:00 , May 23, 2016 |  BioCentury  |  Strategy

Two heads are better

With Gleevec imatinib off patent, flagging ophthalmics sales and at least one slower than expected launch, Novartis AG is consolidating operations at the top to cut costs, while also splitting its R&D into two buckets:...
07:00 , Apr 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase α (PI3Kα); phosphoinositide 3-kinase catalytic subunit α polypeptide (PI3KCA; p110α); mammalian target of rapamycin (mTO

  Cancer INDICATION: Cancer Patient sample and mouse studies suggest inhibiting the PI3Kα/ mTOR pathway could help treat venous malformations. Genetic sequencing identified activating mutations in PI3KCA in venous malformation lesions from patients, and in...
08:00 , Feb 15, 2016 |  BC Week In Review  |  Company News

Radius Health, Novartis deal

The companies partnered to evaluate Radius’ RAD1901 in combination with either Novartis’ ribociclib ( LEE011 ) or the pharma’s alpelisib ( BYL719 ) in studies to treat breast cancer. The partners will share expenses and...
08:00 , Dec 10, 2015 |  BC Innovations  |  Translation in Brief

Beyond furry test tubes

In the largest study of patient-derived xenograft (PDX) mouse models published to date, researchers at Novartis Institutes for BioMedical Research (NIBR) have demonstrated that a high throughput preclinical trial for screening compounds in mice can...